Table 2.

Patient-reported outcome measures in CSU and areas of use

	UAS	CU-Q2oL	UCT	AAS	AE-QoL	AECT
Applicable in patients with:
Wheals and no angioedema	+	+	+	–	–	–
Wheals and angioedema	+	+	+	+	+	+
No wheals and angioedema	–	–	+	+	+	+
Number of items	2	23	4	5	17	4
Retrospective assessment	–	+	+	–	+	+
(recall period)		2 weeks	4 weeks 7 days		4 weeks	4 weeks 3 months
Prospective assessment	+	–	–	+	–	–
(frequency)	1× or 2×/day			1×/day
MCID	11	3–15a	3	8	6	3
Cost-free for:
Patient management	+	+	+	+	+	+
Academic research	+	+	+	+	+	+
Industry studies	+	–	–	–	–	–
Language/country versions availableb	+c	Italian, German, Greek, Hebrew, Korean, Persian, Polish, Portuguese, Spanish, Thai, Turkish	> 90 language versions available	> 80 language versions available	> 50 language versions available	> 40 language versions available

Reproduced from Maurer et al., 2020 under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License [44]

AAS Angioedema Activity Score, AECT Angioedema Control Test, AE-QoL Angioedema Quality of Life Questionnaire, CSU chronic spontaneous urticaria, CU-Q₂oL Chronic Urticaria Quality of Life Questionnaire, MCID minimal clinically important difference, UAS Urticaria Activity Score, UCT Urticaria Control Test

^aThe MCID of the CU-Q₂oL has been assessed in two independent studies performed in different patient collectives in Europe and Asia. While one study found an MCID of 3 points [46], the MCID identified in the other study was higher with 15 points [47]

^bAdditional language/country versions may be or are in preparation

^cThe UAS is available in several languages. The original source is the EAACI/GA²LEN/EDF/WAO urticaria guideline [1]. Due to its easy structure, the UAS is usually translated but not formally linguistically validated